Myeloid Neoplasia

A collection of features and news articles published in ASH Clinical News related to myeloid neoplasia.

Luspatercept Reduces the Need for Transfusions in Patients With Beta Thalassemia and MDS

In two separate phase III trials presented at the 2018 ASH Annual Meeting, luspatercept, a first-in-class recombinant fusion protein, was found to be safe...

Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models

Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...

How I Treat in Brief: Using Molecular Genetic Tests to Evaluate Myelodysplastic Syndromes

David P. Steensma, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, discussed how to use results from molecular genetic tests in...
WIB_icon

No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS

In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...

Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms

A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...

Post-Transplant Gene Mutations Predict Risk for MDS Progression

Sequencing bone marrow samples early after patients with myelodysplastic syndromes (MDS) have undergone allogeneic hematopoietic cell transplantation (AHCT) could help identify patients who are...

Demystifying Epigenetics in Hematology

In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...

In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...

FDA Places Partial Clinical Hold on AML and MDS Trial

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on a phase I/II trial of OXi4503, a vascular disrupting agent...

SHARE